SLC22A1 and chronic myelogenous leukemia, BCR-ABL1 positive: Even though these results could be interpreted as evidence that OCT1 is involved, they have to be handled with reserve especially since there is no consistent findings on OCT1 mRNA expression in leukemic cells and its correlation to therapy response in CML patients [105].